QUOTE AND NEWS
newratings.com  3 hrs ago  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) Tuesday announced that it has entered into a new global collaboration with French drugmaker Sanofi (SNYNF, SNY) to discover, develop and commercialize new antibody cancer treatments in the...
Benzinga  12 hrs ago  Comment 
Regeneron Pharmaceuticals Inc (NASDAQ: REGN)'s cholesterol-lowering drug Praluent recently received approval by the U.S. Food and Drug Administration (FDA). Leonard Schleifer, Regeneron president and CEO, was on CNBC Monday to discuss Praluent...
newratings.com  Jul 24  Comment 
PARIS (dpa-AFX) - Sanofi (SNY) and Regeneron Pharmaceuticals Inc (REGN) on Friday said the U.S. Food and Drug Administration has approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs...
newratings.com  Jul 15  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicine Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion for the marketing authorization of...
Motley Fool  Jul 11  Comment 
Regeneron Pharmaceuticals will hear back from the FDA this month on an approval decision for one of its most promising drug candidates, and investors should be excited about the potential the drug holds.
Benzinga  Jul 9  Comment 
In a report published Thursday, UBS analyst Matthew Roden downgraded the rating on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) from Neutral to Sell, citing the surge in shares, while maintaining a price target of $500. Regeneron's shares have...
newratings.com  Jul 9  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent (alirocumab) Injection met its primary endpoint. At week 24, patients in the Praluent group...
Market Intelligence Center  Jun 30  Comment 
After Monday’s trading in Regeneron Pharmaceuticals Inc (REGN) MarketIntelligenceCenter.com's option trade-picking algorithms uncovered a trade that offers a 4.96% or 34.82% (for comparison purposes only), while providing 5.66% downside...
Benzinga  Jun 29  Comment 
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Proceedings of the National Academy of Sciences (PNAS) has published a paper demonstrating that the Company's proprietary VelociGene® and VelocImmune® technologies enabled...
newratings.com  Jun 26  Comment 
LEVERKUSEN (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare or...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki